COPD and biologic treatment: state of the art.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
12
7
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
ppublish
Résumé
Chronic Obstructive Pulmonary Disease (COPD) is a common, heterogeneous disease associated with abnormal inflammatory response of the lung to noxious particles and gases. The progression of disease leads to respiratory failure, disability and premature death. Although recent progress in reducing the global burden of many chronic disease, such as heart disease and cancer, mortality and morbidity due to COPD continue to increase despite of cigarette smoking worldwide policy. Additionally, diagnostic and therapeutic options have not changed in decades. While patients affected by other respiratory disease may benefit with a personalized precision medicine, thanks to the new biological treatment, to date, there is no biological treatment available for COPD. COPD is generally a neutrophils-predominant disease but approximately 40% of patients with COPD had also an eosinophilic airway inflammation. different Phase III trials have been recently performed to evaluate the efficacy and safety of several biological treatments, mostly against eosinophilic inflammation and, to date, some of this trial, still ongoing have promising results. This review resumes the rationale, the attempts of biological treatment in COPD and latest promising results.
Identifiants
pubmed: 37357768
doi: 10.1097/ACI.0000000000000920
pii: 00130832-202308000-00009
doi:
Substances chimiques
Biological Products
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
309-318Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Eur Respir J 2023; 61:2300239.
WHO. Projections of mortality and causes of death, 2016 to 2060. www.who.int/healthinfo/global_burden_disease/projections/en/Date last accessed: April 5, 2020; date last updated: April 2020.
Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. Lancet 2022; 400:921–972.
Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47:410–419.
Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184:662–671.
Yun JH, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2018; 141:2037–2047.e10.
Sun J, Liu T, Yan Y, et al. The role of Th1/Th2 cytokines played in regulation of specific CD4+ Th1 cell conversion and activation during inflammatory reaction of chronic obstructive pulmonary disease. Scand J Immunol 2018; 88:e12674.
Matera MG, Page C, Rogliani P, et al. Therapeutic monoclonal antibodies for the treatment of chronic obstructive pulmonary disease. Drugs 2016; 76:1257–1270.
Yousuf A, Brightling CE. Biologic drugs: a new target therapy in COPD? COPD 2018; 15:99–107.
Pavord ID. Biologics and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2018; 141:1983–1991.
Fieldes M, Bourguignon C, Assou S, et al. Targeted therapy in eosinophilic chronic obstructive pulmonary disease. ERJ Open Res 2021; 7:00437–2020.
Denburg JA. Bone marrow in atopy and asthma: hematopoietic mechanisms in allergic inflammation. Immunol Today 1999; 20:111–113.
Barnes PJ. Cellular and molecular mechanisms of asthma and COPD. Clin Sci (Lond) 2017; 131:1541–1558.
Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2006; 1:39–47.
Capron T, Bourdin A, Perez T, Chanez P. COPD beyond proximal bronchial obstruction: phenotyping and related tools at the bedside. Eur Respir Rev 2019; 28:190010.
Narendra DK, Hanania NA. Targeting IL-5 in COPD. Int J Chron Obstruct Pulmon Dis 2019; 14:1045–1051.
art TK, Cook RM, Zia-Amirhosseini P, et al. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001; 108:250–257.
EMA, Nucala: Summary Of Product Characteristics. www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf . Date last accessed: 2020; date last updated: 2015.
FDA, Clinical Review - NUCALA (mepolizumab). www.fda.gov/media/95114/download . Date last accessed 2020; date last update 2015.
Dasgupta A, Kjarsgaard M, Capaldi D, et al. A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis. Eur Respir J 2017; 49:1602486.
Study to evaluate efficacy and safety of Mepolizumab for frequently exacerbating chronic obstructive pulmonary disease (COPD) patients - Full text view - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02105948
Efficacy and safety of Mepolizumab as an add-on treatment in chronic obstructive pulmonary disease (COPD) - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02105961
Pavord ID, Chapman KR, Bafadhel M, et al. Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO. Int J Chron Obstruct Pulmon Dis 2021; 16:1755–1770.
https://www.fda.gov/media/114447/download .
Mepolizumab as Add-on Treatment IN participants with COPD characterized by frequent exacerbations and eosinophil level - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04133909
https://www.ema.europa.eu/en/documents/product-information/cinqaero-epar-product-information_en.pdf .
Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy 2020; 75:1023–1042.
Brightling CE, Bleecker ER, Panettieri RA Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014; 2:891–901.
Benralizumab efficacy in moderate to very severe chronic obstructive pulmonary disease (COPD) with exacerbation history - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02138916
Efficacy and safety of Benralizumab in moderate to very severe chronic obstructive pulmonary disease (COPD) with exacerbation history - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02155660
Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the prevention of COPD exacerbations. N Engl J Med 2019; 381:1023–1034.
Criner GJ, Celli BR, Singh D, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respir Med 2020; 8:158–170.
May RD, Fung M. Strategies targeting the IL-4/IL-13 axes in disease. Cytokine 2015; 75:89–116.
Kaur D, Hollins F, Woodman L, et al. Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression. Allergy 2006; 61:1047–1053.
Marone G, Granata F, Pucino V, et al. The intriguing role of interleukin 13 in the pathophysiology of asthma. Front Pharmacol 2019; 10:1387.
Blanchard C, Mishra A, Saito-Akei H, et al. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by antihuman-interleukin-13 antibody (CAT-354). Clin Exp Allergy 2005; 35:1096–1103.
Liu SF, Chang HC, Chang YP, et al. IL13 Promoter (-1055) polymorphism associated with leukocyte mitochondria DNA copy number in chronic obstructive pulmonary disease. Cells 2022; 11:3787.
Ahmadi A, Ghaedi H, Salimian J, et al. Association between chronic obstructive pulmonary disease and interleukins gene variants: a systematic review and meta-analysis. Cytokine 2019; 117:65–71.
Pivotal study to assess the efficacy, safety and tolerability of Dupilumab in patients with moderate-to-severe COPD with type 2 inflammation - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03930732
Study of Remdesivir in participants 18 years old and younger with COVID-19 - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04456673
Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Eng J Med 2023; doi:10.1056/NEJMoa2303951. [Epub ahead of print].
doi: 10.1056/NEJMoa2303951.
A study evaluating the effects of Lebrikizumab on airway Eosinophilic inflammation in participants with uncontrolled asthma - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02099656
Austin CD, Gonzalez Edick M, Ferrando RE, et al. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). Clin Exp Allergy 2020; 50:1342–1351.
A study of Lebrikizumab in adolescent participants with uncontrolled asthma who are on inhaled corticosteroids and a second controller medication - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01875003
Szefler SJ, Roberts G, Rubin AS, et al. Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS). Clin Transl Allergy 2022; 12:e12176.
Anti-interleukin-13 and anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for people with asthma - PMC (nih.gov) https://clinicaltrials.gov/ct2/show/NCT01867125
A study of Lebrikizumab in participants with uncontrolled asthma on inhaled corticosteroids and a second controller medication - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01868061
Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 2016; 4:781–796.
A study to evaluate safety and efficacy of Lebrikizumab in participants with chronic obstructive pulmonary disease (COPD) - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02546700
Popovic B, Breed J, Rees DG, et al. Structural characterisation reveals mechanism of IL-13 neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol 2017; 429:208–219.
Walsh GM. Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD. Curr Opin Investig Drugs 2010; 11:1305–1312.
A phase 3 study to evaluate the efficacy and safety of Tralokinumab in adults and adolescents with uncontrolled asthma - Full Text View - ClinicalTrials.gov https://www.clinicaltrials.gov/ct2/show/NCT02161757
A phase 3 study to evaluate the efficacy and safety of Tralokinumab in adults and adolescents with uncontrolled asthma - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02194699
Panettieri RA Jr, Sjöbring U, Péterffy A, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med 2018; 6:511–525.
Allakhverdi Z, Comeau MR, Jessup HK, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 2007; 204:253–258.
Varricchi G, Pecoraro A, Marone G, et al. Thymic stromal lymph-opoietin isoforms, inflammatory disorders, and cancer. Front Immunol 2018; 9:1595.
Wu J, Dong F, Wang RA, et al. Central role of cellular senes-cence in TSLP- induced airway remodeling in asthma. PLoS One 2013; 8:e77795.
Tezepelumab COPD exacerbation study - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04039113
Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med 2021; 385:1656–1668.
Proof-of-concept study to assess the efficacy, safety and tolerability of SAR440340 (Anti-IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03546907
Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med 2021; 9:1288–1298.
Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/Itepekimab in chronic obstructive pulmonary disease (COPD) - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04701983
Study to assess the efficacy, safety, and tolerability of SAR440340/REGN3500/Itepekimab in chronic obstructive pulmonary disease (COPD) (AERIFY-2) - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04751487
A study to assess the efficacy and safety of MSTT1041A in participants with uncontrolled severe asthma - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02918019
Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. J Allergy Clin Immunol 2021; 148:790–798.
Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP) - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03615040
Yousuf AJ, Mohammed S, Carr L, et al. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. Lancet Respir Med 2022; 10:469–477.
Vogelmeier C, Aquino TO, O’Brien CD, et al. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. COPD 2012; 9:111–120.
Danirixin dose ranging study in participants with chronic obstructive pulmonary disease (COPD) - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03034967
Lazaar AL, Miller BE, Donald AC, et al. CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial. Respir Res 2020; 21:149.
Osei ET, Brandsma CA, Timens W, et al. Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD. Eur Respir J 2020; 55:1900563.
https://clinicaltrials.gov/ct2/show/NCT00581945 .
Novartis. Safety and efficacy of multiple doses of canakinumab (ACZ885) in chronic obstructive pulmonary disease (COPD) patients. 2007. https://clinicaltrials.gov/ct2/show/NCT00581945 Date last updated: June 30, 2011. Date last accessed: March 10, 2019.
Rogliani P, Calzetta L, Ora J, Matera MG. Canakinumab for the treatment of chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2015; 31:15–27.
A study to evaluate the efficacy of MEDI8968 in chronic obstructive pulmonary disease - Full Text View - ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01448850
Calverley PMA, Sethi S, Dawson M, et al. A randomised, placebo-controlled trial of antiinterleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. Respir Res 2017; 18:153.